CG ONCOLOGY, INC. COMMON STOCK
NASDAQ: CGON (CG Oncology, Inc.)
Kemas kini terakhir: 2 jam lalu67.38
-0.97 (-1.42%)
| Penutupan Terdahulu | 68.35 |
| Jumlah Dagangan | 1,542,485 |
| Harga / Jualan (P/S) | 971.07 |
| Harga / Buku (P/B) | 6.32 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -81,161.54% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -90.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.15% |
| Nisbah Semasa (MRQ) | 30.97 |
| Aliran Tunai Operasi (OCF TTM) | -81.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -57.18 M |
| Pulangan Atas Aset (ROA TTM) | -12.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | CG Oncology, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.83 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.17% |
| % Dimiliki oleh Institusi | 105.34% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |